.avif)
Agios Pharmaceuticals Email Format
Pharmaceutical Manufacturing
・
501-1,000 employees
・
Cambridge, MA, USA
Agios Pharmaceuticals is a commercial-stage biopharmaceutical company dedicated to developing and delivering innovative medicines for rare diseases, with deep expertise rooted in hematology.
Search our verified sources for decision-makers, emails, and titles.
Start searching
VERIFIED BY CLAY
first.last@agios.com
Company Overview
Industry
Pharmaceutical Manufacturing
Founded
2008
Headquarters
Cambridge, MA, USA
Revenue
$25M-$50M
FUNDING Stage
Public
Website
Key Executives
Brian Goff (chief executive officer), Cecilia Jones (Chief Financial Officer), Krishnan Viswanadhan (Chief Strategy and Operations Officer)
Tech Stack
Key Executives
4.9/5 on G2
40K+ GTM professionals
SOC 2 Type II certified
Frequently Asked Questions
What is the email format of Agios Pharmaceuticals?
Agios Pharmaceuticals uses the first.last format, so Jane Smith would be jane.smith@agios.com.
What approved medicines does Agios Pharmaceuticals currently market in the United States?
Agios Pharmaceuticals markets two approved medicines in the U.S.: PYRUKYND (mitapivat) for adults with pyruvate kinase deficiency, and AQVESME (mitapivat), which launched in early 2026 as the only FDA-approved treatment for anemia in adults with alpha- or beta-thalassemia.
Where is Agios Pharmaceuticals headquartered, and how large is the company?
Agios Pharmaceuticals is headquartered in Cambridge, MA. The company has approximately 656 employees and operates as a commercial-stage biopharmaceutical company focused on rare hematologic diseases.
How can I find and verify contact details for specific Agios Pharmaceuticals team members?
Since Agios Pharmaceuticals uses the first.last@agios.com format, you can build email addresses directly once you have a contact's name. Tools like Clay can help you verify those addresses and enrich prospect lists with additional details like role, seniority, or department.
What rare disease areas does Agios Pharmaceuticals focus on beyond thalassemia in its pipeline?
Beyond thalassemia, Agios Pharmaceuticals is advancing programs in sickle cell disease, pyruvate kinase deficiency in pediatric patients, lower-risk myelodysplastic syndromes, polycythemia vera, and phenylketonuria, all grounded in the company's expertise in cellular metabolism and PK activation.
Get access to more people and company data using Clay
Leverage the power of 100+ data providers for industry-leading data coverage & quality.
4.9 rating